Published in J Bone Miner Res on August 01, 2000
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
Assessment of fracture risk. Osteoporos Int (2004) 5.15
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res (2010) 2.52
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab (2009) 2.20
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women. J Clin Endocrinol Metab (2008) 1.82
Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab (2013) 1.69
Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation. Menopause (2012) 1.66
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (2015) 1.57
Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int (2006) 1.52
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Sex-hormone-binding globulin is negatively correlated with femoral bone-mineral density in male cardiac-transplant recipients. Wien Klin Wochenschr (2004) 1.38
Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int (2009) 1.37
Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33
Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab (2012) 1.27
The assessment of fracture risk. J Bone Joint Surg Am (2010) 1.27
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int (2006) 1.21
The clinical utility of bone marker measurements in osteoporosis. J Transl Med (2013) 1.21
Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med (2012) 1.17
Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass: the cardiovascular health study. J Clin Endocrinol Metab (2011) 1.15
Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res (2009) 1.13
Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol (2005) 1.11
Associations of serum sex hormone-binding globulin and sex hormone concentrations with hip fracture risk in postmenopausal women. J Clin Endocrinol Metab (2008) 1.08
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract (2009) 1.06
Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study - how useful is the current clinical gold standard for fracture risk? Clin Interv Aging (2015) 1.06
Estrogen receptor α36 mediates a bone-sparing effect of 17β-estrodiol in postmenopausal women. J Bone Miner Res (2011) 1.04
Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab (2008) 1.02
Bone quality: an empty term. PLoS Med (2007) 1.00
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int (2007) 1.00
National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int (2012) 0.99
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Homocysteine and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int (2007) 0.94
Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int (2007) 0.94
Effect of antioxidants combined to resistance training on BMD in elderly women: a pilot study. Osteoporos Int (2008) 0.94
Vitamin D insufficiency in adolescent males in Southern Tasmania: prevalence, determinants, and relationship to bone turnover markers. Osteoporos Int (2004) 0.93
Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol (2006) 0.93
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int (2007) 0.92
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.88
Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal women. Int J Endocrinol (2013) 0.88
Association between DHEAS and bone loss in postmenopausal women: a 15-year longitudinal population-based study. Calcif Tissue Int (2011) 0.87
Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women. Osteoporos Int (2009) 0.87
Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. J Bone Miner Res (2008) 0.86
Focal therapeutic irradiation induces an early transient increase in bone glycation. Radiat Res (2014) 0.86
Common polymorphisms rather than rare genetic variants of the Runx2 gene are associated with femoral neck BMD in Spanish women. J Bone Miner Metab (2010) 0.86
Endogenous sex steroids and bone mineral density in healthy Greek postmenopausal women. J Bone Miner Metab (2006) 0.86
The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab (2008) 0.85
Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr (2009) 0.85
Urinary excretion of type I collagen cross-linked N-telopeptide and serum bone-specific alkaline phosphatase analysis to determine the correlation of age and back-pain related changes in elderly women. J Bone Miner Metab (2005) 0.85
A hospital based study of biochemical markers of bone turnovers & bone mineral density in north Indian women. Indian J Med Res (2013) 0.84
Bone turnover and body weight relationships differ in normal-weight compared with heavier postmenopausal women. Osteoporos Int (2003) 0.84
Serum sex steroid levels and longitudinal changes in bone density in relation to the final menstrual period. J Clin Endocrinol Metab (2013) 0.84
Successes achieved and challenges ahead in translating biomarkers into clinical applications. AAPS J (2010) 0.84
Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women-the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int (2006) 0.84
Vasomotor symptoms in infertile premenopausal women: a hitherto unappreciated risk for low bone mineral density. Fertil Steril (2008) 0.83
Incidence and risk factors for osteoporotic vertebral fracture in low-income community-dwelling elderly: a population-based prospective cohort study in Brazil. The São Paulo Ageing & Health (SPAH) Study. Osteoporos Int (2014) 0.82
A cross-sectional association between bone mineral density and parathyroid hormone and other biomarkers in community-dwelling young adults: the CARDIA study. J Clin Endocrinol Metab (2013) 0.82
The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int (2008) 0.82
Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group. Wien Med Wochenschr (2012) 0.82
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Med Press) (2012) 0.82
Association between endogenous plasma hormone concentrations and fracture risk in men and women: the EPIC-Oxford prospective cohort study. J Bone Miner Metab (2009) 0.82
Bone loss and the risk of non-vertebral fractures in women and men: the Tromsø study. Osteoporos Int (2009) 0.81
Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers. Biomark Cancer (2011) 0.81
Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int (2009) 0.81
Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study. Osteoporos Int (2009) 0.81
Predictors of re-fracture amongst patients managed within a secondary fracture prevention program: a 7-year prospective study. Osteoporos Int (2014) 0.81
Relationship between mandibular inferior cortex and general bone metabolism in older adults. Osteoporos Int (2007) 0.81
Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial. Osteoporos Int (2009) 0.81
Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int (2012) 0.81
Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women. J Bone Miner Metab (2006) 0.80
Genetic influence on bone phenotypes and body composition: a Swedish twin study. J Bone Miner Metab (2013) 0.80
Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products. Nutr Res Rev (2014) 0.80
Collaborative cross mice in a genetic association study reveal new candidate genes for bone microarchitecture. BMC Genomics (2015) 0.79
Socioeconomic status, race, and bone turnover in the Midlife in the US Study. Osteoporos Int (2011) 0.79
Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol (2009) 0.79
The Protective Effect of Cordymin, a Peptide Purified from the Medicinal Mushroom Cordyceps sinensis, on Diabetic Osteopenia in Alloxan-Induced Diabetic Rats. Evid Based Complement Alternat Med (2013) 0.79
Telomerase activity promotes osteoblast differentiation by modulating IGF-signaling pathway. Biogerontology (2015) 0.78
The effects of Cordyceps sinensis phytoestrogen on estrogen deficiency-induced osteoporosis in ovariectomized rats. BMC Complement Altern Med (2014) 0.78
Relationship of circulating MMP-2, MMP-1, and TIMP-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women. Osteoporos Int (2005) 0.78
Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population. Bone (2015) 0.78
An altered hormonal profile and elevated rate of bone loss are associated with low bone mass in professional horse-racing jockeys. J Bone Miner Metab (2012) 0.77
Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis. J Bone Miner Metab (2013) 0.77
Effect of weight loss on bone health in overweight/obese postmenopausal breast cancer survivors. Breast Cancer Res Treat (2015) 0.77
Alendronate sodium in the management of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Osteoprotective effect of cordycepin on estrogen deficiency-induced osteoporosis in vitro and in vivo. Biomed Res Int (2015) 0.77
Determination of mineral content in methanolic safflower (Carthamus tinctorius L.) seed extract and its effect on osteoblast markers. Int J Mol Sci (2009) 0.77
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporos Int (2009) 0.77
Teriparatide and denosumab combination therapy and skeletal metabolism. Osteoporos Int (2016) 0.76
Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid. Osteoporos Int (2009) 0.76
Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab (2008) 0.76
The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research Group. J Bone Miner Metab (2006) 0.76
Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab (2016) 0.75
The clinical contribution of cortical porosity to fragility fractures. Bonekey Rep (2016) 0.75
Effect of self-reported walking difficulty on bone mass and bone resorption marker in Japanese people aged 40 years and over. J Physiol Anthropol (2016) 0.75
Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer. PLoS One (2017) 0.75
Antiosteoporotic effect of orally administered yolk-derived peptides on bone mass in women. Food Sci Nutr (2014) 0.75
Obesity, Type 2 Diabetes and Bone in Adults. Calcif Tissue Int (2017) 0.75
Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med (1992) 9.86
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Dietary supplementation in elderly patients with fractured neck of the femur. Lancet (1990) 4.47
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Do we need to change the WHO definition of osteoporosis? Osteoporos Int (2000) 3.35
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet (1996) 2.83
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ (1994) 2.61
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem (1998) 2.48
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab (1994) 2.39
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
The role of collagen in bone strength. Osteoporos Int (2005) 2.19
Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis (2001) 2.18
Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev (2006) 2.08
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab (1997) 2.04
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum (2000) 1.85
Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab (1990) 1.83
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone (1996) 1.80
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest (1993) 1.78
Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. J Bone Miner Res (1998) 1.77
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab (1988) 1.71
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet (1994) 1.71
How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int (1998) 1.70
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest (1983) 1.69
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res (2003) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner (1990) 1.62
The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol (1998) 1.59
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum (2001) 1.58
Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int (1993) 1.58
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer (2000) 1.56
Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone (2003) 1.54
Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab (1996) 1.53
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med (1995) 1.48
Serum and synovial fluid osteocalcin (bone gla protein) levels in joint disease. Br J Rheumatol (1989) 1.48
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) J Clin Endocrinol Metab (1997) 1.48
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int (2007) 1.47
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res (1997) 1.42
Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res (1997) 1.42
Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone (1999) 1.41
Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int (2006) 1.41
Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int (2000) 1.41
Incorporation and distribution of strontium in bone. Bone (2001) 1.40
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res (1997) 1.39
Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther (1999) 1.35
Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab (1993) 1.34
Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33
Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab (2001) 1.30
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab (1991) 1.30
Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture. Osteoporos Int (2006) 1.30
Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet (2000) 1.28
Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone (2006) 1.27
Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage (1998) 1.26
The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone (2002) 1.26
Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone (2004) 1.25
Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab (2003) 1.23
Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone (1998) 1.23
Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study. Osteoporos Int (2005) 1.22
Different morphometric and densitometric parameters predict cervical and trochanteric hip fracture: the EPIDOS Study. J Bone Miner Res (1997) 1.22
The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest (1999) 1.21
Body composition in appropriate and in small for gestational age infants. Acta Paediatr (1997) 1.21
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int (2001) 1.20
Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. Bone (2000) 1.20
Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. J Pediatr (2001) 1.20
Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int (2001) 1.20
Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res (1999) 1.19
Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int (2002) 1.19
Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int (2012) 1.19
Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int (2006) 1.18
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) (2004) 1.18
Cross-sectional assessment of age-related bone loss in men: the MINOS study. Bone (2000) 1.17
Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res (1993) 1.17
Hemodynamic and hormonal responses to hypothermic and normothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth (1992) 1.17
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
Ultrasound discriminates patients with hip fracture equally well as dual energy X-ray absorptiometry and independently of bone mineral density. J Bone Miner Res (1995) 1.16
Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab (2001) 1.16
Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int (2012) 1.13
Collagen Ialpha1 Sp1 polymorphism, bone mass, and bone turnover in healthy French premenopausal women: the OFELY study. J Bone Miner Res (1998) 1.13
Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis (2003) 1.12